Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2922)	11/2/2013 8:53:40 PM
From: jq1234si	Read Replies (1) \| Respond to of 4474

Hypertension was the most frequent AEs from PACE by wide margin, both any grade and grade 3/4, in 60-70%, 30-40% patients respectively.

To: Biomaven who wrote (2922)	11/3/2013 6:22:06 AM
From: GregorioAllegri	1 Recommendation Recommended By jq1234si Respond to of 4474

From the US Label for each product. For Ponatinib the results are from PACE without a doubt. Percent of Patients with Hypertension, Any Grade Compound...........VEGFR2 IC50.....Use Rate (mg)...% Hypertension VEGFR2 Inhibitors Ponatinib....................1.5............45..............68% Sunitinib....................10...............50............28-47% Sorafenib.................15-90.........400..............17% Cabozantinib.............1.3............140..............61% NOT VEGFR2 Inhibitors Imatinib...................>2000..........400............0.1-1% Dasatinib.............2000-5000...100-140..........1% Nilotinib....................5300.........300-400.......1-10% Bosutinib...............>2000...........500..............0.1-1%